Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, gives an overview of treatment options for patients with lymphoma who are ineligible for autologous stem cell transplantation (autoSCT), drawing focus on the growing role of novel targeted therapies and immunotherapies. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Research funding from Seattle Genetics, BMS, Affimed, Regeneron, Takeda, AstraZeneca, Pfizer, ADC Therapeutics to my institution for clinical trials.